

## Transforming women's health through innovation

### Company overview

Mithra is a Belgian **biotech company** created in 1999 dedicated to transforming **Women's Health** by offering new choices through innovation based on a unique molecule, Estetrol (E4), a native estrogen that offers a differentiated benefit/risk profile compared to existing hormone-based solutions.

Thanks to the commitment of its employees based on two sites, among which a majority of women, Mithra stands by its goals to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span.

Mithra relies on **two complementary innovative platforms**: an Estetrol-based portfolio and Complex Therapeutics which are complemented by a unique manufacturing facility, Mithra CDMO and leveraged by Mithra's know-how in **long-acting drug development** using polymer technology.

### Global strategy

#### Women's health

**Estelle®** is a contraceptive pill designed to improve women's contraceptive experience as it showed a favorable safety profile, a higher user satisfaction with improved quality of life and a low risk of drug-drug interaction.

**Donesta®** is a next generation orally-administrated estetrol-based hormone therapy product candidate.

#### and beyond

Neuroprotection and wound healing.

#### Complex therapeutics

**Myring®** Contraception

**Tibelia®** Menopause

**Zoreline®** Oncology

### R&D pipeline

	Product	Indication	Preclinical	Phase I	Phase II	Phase III	Commercialization
E4	<b>Estelle®</b>	Contraception	[Progress bar spanning Preclinical, Phase I, Phase II, Phase III, and Commercialization]				
	<b>Donesta®</b>	Menopause	[Progress bar spanning Preclinical, Phase I, Phase II, and Phase III]				
	-	Neuroprotection	[Progress bar spanning Preclinical and Phase I]				
	-	Wound healing	[Progress bar spanning Preclinical and Phase I]				
COMPLEX THERAPEUTICS	<b>Myring®</b>	Contraception	[Progress bar spanning Preclinical, Phase I, Phase II, Phase III, and Commercialization]				
	<b>Tibelia®</b>	Menopause	[Progress bar spanning Preclinical, Phase I, Phase II, Phase III, and Commercialization]				
	<b>Zoreline®</b>	Oncology	[Progress bar spanning Preclinical and Phase I]				

## Management



**David Horn Solomon**  
Chief Executive Officer (CEO)



**Christophe Maréchal**  
Chief Financial Officer (CFO)



**Graham Dixon**  
Chief Scientific Officer (CSO)

## ESG Rating




## Financial overview

(in EUR million)



## Share information

Number of outstanding shares



Shareholders

%  
(8 June 2023)

Marc Coucke	4,77 %
Noshaq	9,38 %
François Fornieri	18,48 %
Other shareholders (<5%)	67,37 %

## Cash position



## Analyst Coverage



Last updated June 2023



### Stay in touch!

Subscribe to our mailing list:  
[www.mithra.com/en/newsletter/](http://www.mithra.com/en/newsletter/)



### Further information

[investorrelations@mithra.com](mailto:investorrelations@mithra.com)  
<https://www.mithra.com/en/investors/>